膀胱健康问题居家尿液自测的可接受性:一项定性研究。
完整摘要 · 中文译文
背景:血尿可能是膀胱癌的征兆。YORKSURe可行性研究评估了在家进行血尿试纸自测,以为未来膀胱癌筛查的有效性试验提供依据。潜在参与者通过邮寄收到自测试剂盒,并被要求进行2-6次试纸检测。参与者通过应用程序将图像发送给试验团队或通过电话报告结果(将其试纸条颜色与图表匹配并输入相应编号)。试纸检测五项参数,参与者被随机分配以揭示不同的面板结果。结果预设为异常者被提供在社区诊所进一步检查。我们定性探讨了尿液自测、自我报告结果、随访检测及试验设计(包括揭示/隐藏结果)的可接受性,以及参与者接收结果的体验和检测的障碍与促进因素。 方法:我们开展了半结构化访谈,以可接受性理论框架为依据。我们按参与情况、检测结果和社会经济剥夺程度目的性抽样了应答者和无应答者。我们使用框架法对逐字转录稿进行了主题分析。 结果:我们访谈了29人:21名应答者、6名无应答者和2名在试纸检测结果异常后到早期检测诊所就诊者。尿液自测的想法是可接受的。许多人觉得自己有能力采集和检测自己的尿液并报告结果。对其他人而言,采集尿液所需的规定 rine增加了感知复杂性,且需要自我报告结果使检测令人感到负担。结果虽被理解,但一些人期望不止一项结果。异常结果的随访检测是预期中的。检测最常见的障碍是邀请的时机。最常见的促进因素是对健康的兴趣和过去的健康经历。对于隐瞒结果的可接受性存在混合观点,并对隐瞒异常结果存在担忧。 结论:总体而言,大多数人认为试剂盒和自我报告是可接受的。简化说明可以提高可接受性。在任何未来试验中可进一步解释隐瞒做法。 临床试验注册:YORKSURe于2022年6月9日在ISRCTN注册,注册号为34273159。
完整摘要 · 英文原文
BACKGROUND: Haematuria can be a sign of bladder cancer. The YORKSURe feasibility study assessed at-home haematuria dipstick self-testing to inform future effectiveness trials of screening for bladder cancer. Potential participants were mailed self-testing kits and asked to undertake 2-6 dipstick tests. Participants reported results using an app to send the image to the trial team or by phone (matching their test strip colour to a chart and entering the corresponding number). The dipstick tested five parameters and participants were randomised to reveal different panel outcomes. Those with predefined abnormal results were offered further investigation in community clinics. We qualitatively explored the acceptability of urine self-testing, self-reporting results, follow-up tests and the trial design (including revealing/concealing results) in addition to participants' experience receiving the results and barriers and facilitators to the test. METHODS: We carried out semi-structured interviews, informed by the Theoretical Framework of Acceptability. We purposively sampled responders and non-responders by participation, test result and socioeconomic deprivation. We analysed verbatim transcripts thematically using the Framework method. RESULTS: We interviewed 29 people: 21 responders, 6 non-responders, and 2 people who attended an early detection clinic following abnormal dipstick findings. The idea of urine self-testing was acceptable. Many people felt capable of collecting and testing their urine and reporting the results. For others, the stipulations required to collect the urine increased the perceived complexity and the need to self-report the results made the test feel burdensome. Results were understood though some people expected more than one result. Follow-up tests for abnormal results were expected. The most common barrier to testing was timing of the invitation. The most common facilitators were interest in health and past health experiences. There were mixed views on the acceptability of concealing results and concerns around concealing abnormal results. CONCLUSIONS: On balance, most people found the kit and self-reporting acceptable. Simplifying instructions could improve acceptability. Concealment could be further explained in any future trial. CLINICAL TRIAL REGISTRATION: YORKSURe was registered with the ISRCTN on 09 June 2022 under Registration Number 34273159.